How is Dato-DXd redefining first-line mTNBC? In this episode of CHM Conversations, Dr. Hope Rugo and Dr. Rebecca Shatsky discuss the TROPION-Breast02 trial results and how this data fits into the broader landscape alongside the ASCENT-03 findings.

The clinicians focus on the shift toward frontline Trop2-directed strategies and how these agents are challenging the chemotherapy-only paradigm. They also address the practicalities of management—specifically managing stomatitis and ocular toxicity while navigating CNS disease and supportive care.

An essential resource for oncology clinicians navigating the future of precision ADC therapy in triple-negative breast cancer.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#TripleNegativeBreastCancer #TNBC #MetastaticBreastCancer #ADCtherapy #SacituzumabGovitecan #DatopotamabDeruxtecan #Trop2 #BreastOncology #MedicalOncology #PrecisionOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Can earlier ESR1 mutation detection help delay progression and preserve quality of life? In this episode of CHM Conversations, Dr. Hope Rugo and Dr. Rebecca Shatsky discuss the evolving role of oral SERDs and ctDNA monitoring in HR+ mBC.

The conversation centers on the SERENA-6 trial and the strategy of identifying ESR1 mutations before radiographic progression. Dr. Rugo and Dr. Shatsky explore how intervening earlier with camizestrant—while maintaining the CDK4/6 inhibitor backbone—may prolong progression-free survival and delay the transition to more intensive chemotherapy or ADCs.

The clinicians examine how these mutations develop as acquired resistance and discuss the broader shift away from the traditional “wait for progression” approach. They also address the real-world logistics of precision medicine, including testing frequency, quantitative monitoring, and the potential to reduce the frequency of traditional scans.

A valuable discussion for oncology clinicians navigating endocrine resistance and the future of biomarker-driven care in metastatic breast cancer.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #ESR1 #OralSERD #Camizestrant #SERENA6 #ctDNA #LiquidBiopsy #PrecisionOncology #CDK46 #EndocrineTherapy #PIK3CA #TargetedTherapy #MedicalOncology #BreastOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How are clinicians navigating the complex balance between immunotherapy and antibody-drug conjugates?

In this episode of CHM Conversations, Dr. Neil Iyengar and Dr. Ticiana Leal discuss the integration of Dato-DXd into the rapidly evolving treatment paradigms for breast and lung cancer.

The experts break down the practicalities of sequencing these therapies, moving beyond traditional chemotherapy to determine where ADCs fit alongside immunotherapy and other targeted agents. The discussion covers everything from biomarker-driven selection to the proactive management of toxicities like ILD and ocular effects, providing a roadmap for optimizing long-term sequencing and patient quality of life.

An essential watch for oncology clinicians managing the integration of next-generation targeted therapies into modern clinical practice.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #LungCancer #NSCLC #ADC #AntibodyDrugConjugates #DatopotamabDeruxtecan #TrastuzumabDeruxtecan #TROP2 #HER2 #EGFR #TargetedTherapy #PrecisionOncology #MedicalOncology #ThoracicOncology #BreastOncology #Immunotherapy #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Can molecular monitoring help clinicians intervene earlier to extend the benefit of first-line therapy?

In this episode of CHM Conversations, Dr. Neil Iyengar, Dr. Manali Bhave, and Dr. Reshma Mahtani discuss overcoming resistance in HR+ mBC.

The conversation focuses on the SERENA-6 trial and the strategy of using serial ctDNA monitoring to catch ESR1 mutations before radiographic progression. Dr. Neil Iyengar, Dr. Manali Bhave, and Dr. Reshma Mahtani break down the practicalities of sequencing endocrine therapies and other targeted therapies, and specifically how a proactive switch to camizestrant may delay the transition to chemotherapy.

Beyond the data, the clinicians address real-world challenges—from navigating insurance and workflow logistics to managing the emotional impact of "molecular progression" and side effects like

photopsia.

An essential update for oncology clinicians looking to optimize treatment sequencing and patient quality of life.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #ESR1 #Camizestrant #SERENA6 #OralSERD #ctDNA #LiquidBiopsy #PrecisionOncology #CDK46 #EndocrineTherapy #PIK3CA #TargetedTherapy #MedicalOncology #BreastOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Are we moving past the traditional "wait for progression" model in HR+ mBC? In this episode of CHM Conversations, Dr. Megan Kruse and Dr. Carol Tweed examine how molecular resistance monitoring is redefining the treatment timeline.

The discussion highlights the shift toward a proactive approach, focusing on the clinical utility of serial ctDNA testing as seen in the SERENA-6 trial. Dr. Kruse and Dr. Tweed discuss how identifying ESR1 mutations early allows for a more precise transition to oral SERDs, helping to preserve endocrine sensitivity and delay the need for more aggressive ADC or chemotherapy regimens.

The clinicians also dive into the nuances of sequencing endocrine therapies and other targeted therapies, and specifically how molecular data helps time the move to next-generation agents. They address the "real-world" side of precision medicine—from implementing liquid biopsy workflows and navigating insurance to managing patient anxiety and monitoring for treatment-related side effects.

A valuable perspective for oncology clinicians looking to master the next generation of biomarker-driven care.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #ESR1 #OralSERD #Camizestrant #SERENA6 #ctDNA #LiquidBiopsy #PrecisionOncology #TargetedTherapy #EndocrineTherapy #CDK46 #ADC #MedicalOncology #BreastOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

What if we could change treatment before scans show progression? In this episode of CHM Conversations, Dr. Jason Mouabbi and Dr. Ahmed Elkhanany explore the impact of ESR1 mutations and the clinical shift toward "molecular progression" in HR+ mBC.

The discussion breaks down the SERENA-6 trial and how early ctDNA detection may allow clinicians to switch therapy before radiologic progression occurs. Dr. Mouabbi and Dr. Elkhanany highlight how precision oncology is reshaping strategy, specifically looking at how oral SERDs like camizestrant can extend endocrine sensitivity and delay more intensive treatments.

The clinicians also examine the transition away from traditional RECIST-based decision-making. They address the practicalities of routine ctDNA testing, patient communication, and what community oncologists should expect as these biomarker-driven approaches move closer to standard practice.

A compelling discussion on the future of proactive intervention and earlier care in metastatic breast cancer.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #HRPositive #Oncology #ESR1 #ctDNA #SERENA6 #Camizestrant #EndocrineTherapy #PrecisionOncology #MedicalOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How are clinicians navigating the growing number of targeted therapy options in HR-positive, HER2-negative metastatic breast cancer?

In this CHM Conversations episode, Drs. Rebecca Shatsky and Reva Basho discuss the critical role of genomic profiling—specifically PIK3CA, AKT, PTEN, and ESR1—in guiding second-line treatment for HR+/HER2- metastatic breast cancer.

The panel compares the clinical use of alpelisib, capivasertib, and inavolisib, focusing on how to sequence these agents after progression on CDK4/6 inhibitors. The experts share practical strategies for managing class-specific toxicities and discuss the future of oral SERDs and combination therapies in personalizing patient care.

A valuable discussion for oncologists and healthcare professionals navigating precision medicine and targeted sequencing strategies in breast oncology.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #Oncology #PIK3CA #AKT #PTEN #Capivasertib #Alpelisib #Inavolisib #ctDNA #PrecisionOncology #TargetedTherapy #MedicalOncology #BreastOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How are clinicians optimizing the use of AKT inhibitors in HR-positive metastatic breast cancer?

In this CHM Conversations episode, Drs. Neil Iyengar, Manali Bhave, and Reshma Mahtani explore the shifting second-line landscape for HR+/HER2- metastatic breast cancer. The discussion centers on the clinical integration of capivasertib and the necessity of biomarker testing—specifically PIK3CA, AKT, PTEN, and ESR1—following progression on CDK4/6 inhibitors.

The panel emphasizes a proactive approach to toxicity, detailing how multidisciplinary care and early metabolic optimization can mitigate class-specific side effects like hyperglycemia, rash, and diarrhea. By focusing on patient education and glycemic control from the start of the treatment journey, clinicians can effectively balance the potent efficacy of PI3K/AKT/PTEN pathway inhibition with long-term tolerability.

A valuable discussion for oncology clinicians navigating biomarker-driven care and targeted therapy management in metastatic breast cancer.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #Oncology #PIK3CA #AKT #PTEN #Capivasertib #Truqap #PrecisionOncology #TargetedTherapy #EndocrineTherapy #MedicalOncology #BreastOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

How is molecular profiling reshaping HR+ metastatic breast cancer treatment?

In this episode of CHM Conversations, Dr. Erica Mayer and Dr. Seth Wander navigate the evolving landscape of endocrine resistance and the PI3K/AKT pathway. They discuss the shifting roles of ESR1 and PIK3CA mutations, the rise of ctDNA in clinical sequencing, and the practicalities of integrating newer therapies like capivasertib.

From proactive toxicity monitoring to the future of combination care, this discussion explores the next era of precision medicine in HR+ breast cancer.

An essential resource for clinicians navigating the future of endocrine therapy and targeted treatment strategies.

🎧 Watch more expert-led oncology conversations from CHM Conversations.

#BreastCancer #HRPositive #Oncology #PIK3CA #ESR1 #ctDNA #Capivasertib #EndocrineTherapy #PrecisionOncology #MedicalOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Can early intervention change the course of metastatic HR+ breast cancer?

In this expert discussion, Dr. Seth Wander and Dr. Erica Mayer break down the practice-changing SERENA-6 trial and the emerging role of camizestrant in ESR1-mutated metastatic breast cancer.

From ctDNA monitoring and early resistance detection, to quality-of-life improvements and precision endocrine therapy—they explore how oral SERDs may redefine treatment sequencing in HR-positive, HER2-negative disease.

Topics include:

• SERENA-6 trial design and results

• ESR1 mutations and endocrine resistance

• ctDNA-guided treatment decisions

• Quality-of-life outcomes with camizestrant

• Oral SERDs vs aromatase inhibitors

• The future of precision endocrine therapy

🎧 Watch now on Community Health Media.

#BreastCancer #HRPositive #ESR1 #Camizestrant #SERENA6 #Oncology #BreastOncology #PrecisionOncology #ctDNA #OralSERD #MetastaticBreastCancer #CancerResearch #MedicalOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media